2022 World Conference on Lung Cancer (ePosters)-EP05.02-007. Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery

EP05.02-007. Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery

Back to course

Pdf Summary

This case report discusses the use of neoadjuvant DS-8201, a targeted therapy, in a 58-year-old Chinese female with stage III non-small cell lung cancer (NSCLC) and HER2 20ins mutation. The patient was asymptomatic and had no previous history of smoking. The diagnosis was made through PET-CT and confirmed by biopsy, which revealed adenocarcinoma with mediastinal lymph node metastases.<br /><br />The patient received treatment with DS-8201, and a partial response was observed according to RECIST 1.1 criteria. The patient experienced grade 1 drug-related adverse events such as nausea, vomiting, and alopecia. After undergoing VATS LUL lobectomy, no extensive chest wall adhesion, fibrosis, or neovascular formation was found during surgery.<br /><br />Pathological examination showed acinar-predominant adenocarcinoma with 80% viable tumor and 20% stroma. Ki67 was 8%, PD-L1 expression was 1%, and HER2 was positive. One out of thirty resected lymph nodes was found to have metastasis in the paratracheal area. Pathologic staging was ypT1bN2M0 (IIIA), indicating a successful R0 resection.<br /><br />The report concludes that DS-8201 demonstrated anticancer activity in this case of localized advanced NSCLC with minimal side effects and without delaying surgery. This suggests that DS-8201 may be a promising neoadjuvant treatment option for HER2 20ins NSCLC patients. However, more research is needed to further investigate the efficacy and safety of DS-8201 in early and localized advanced NSCLC cases.

Asset Subtitle

Katharina Sinn

Meta Tag

Speaker Katharina Sinn

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

neoadjuvant DS-8201

targeted therapy

NSCLC

HER2 20ins mutation

adenocarcinoma

metastasis

pathologic staging

R0 resection

anticancer activity

surgery